Verrica Pharmaceuticals (VRCA) reported significant growth in YCANTH® dispensed applicator units for Q1 2025, reaching 10,102 units - a 16.7% sequential increase from Q4 2024's 8,654 units.
The company attributes this growth to their recent commercial restructuring and normalized distribution inventory levels. With stabilized channel inventory, the dispensed units are expected to more closely track demand and gross revenue going forward.
The management highlighted that strong market access, normalized inventory levels, and a focused commercial team building relationships within dermatology and pediatric communities position YCANTH® for sustainable revenue growth. The company aims to establish YCANTH® as the standard treatment for molluscum contagiosum.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.